Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 10, 2012, Pages 1079-1087

  Ordás, Ingrid ^a   Feagan, Brian G ^b   Sandborn, William J ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's Disease; Inflammatory Bowel Disease; Therapeutic Monitoring; Tumor Necrosis Factor Antagonists; Ulcerative Colitis

Indexed keywords

ALBUMIN; AZATHIOPRINE; C REACTIVE PROTEIN; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL PRACTICE; CROHN DISEASE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; DRUG TREATMENT FAILURE; ENTERITIS; HALF LIFE TIME; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; PROTEIN DEGRADATION; REMISSION; RETICULOENDOTHELIAL SYSTEM; TREATMENT RESPONSE; ULCERATIVE COLITIS;

DRUG MONITORING; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866457923     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.06.032     Document Type: Article

References (49)

1. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
2. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
3. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
4. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
5. Reinisch W., Sandborn W.J., Hommes D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
6. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265. e1-3.
7. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260. quiz, 520.
8. Lichtenstein G.R., Yan S., Bala M., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
9. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
10. Bendtzen K., Ainsworth M., Steenholdt C., et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009, 44:774-781.
11. Wolbink G.J., Voskuyl A.E., Lems W.F., et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:704-707.
12. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
13. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
14. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
15. Radstake T.R., Svenson M., Eijsbouts A.M., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
16. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
17. Steenholdt C., Bendtzen K., Brynskov J., et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011, 46:310-318.
18. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
19. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
20. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
21. Ainsworth M.A., Bendtzen K., Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008, 103:944-948.
22. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
23. Wang S.L., Ohrmund L., Hauenstein S., et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012, 382:177-188.
24. Steenholdt C., Svenson M., Bendtzen K., et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 34:51-58.
25. Lichtenstein G.R., Diamond R.H., Wagner C.L., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
26. Fasanmade A.A., Adedokun O.J., Ford J., et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009, 65:1211-1228.
27. Mould D.R., Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. Biodrugs 2010, 24:23-39.
28. Morell A., Terry W.D., Waldmann T.A. Metabolic properties of IgG subclasses in man. J Clin Invest 1970, 49:673-680.
29. Fasanmade A.A., Adedokun O.J., Olson A., et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010, 48:297-308.
30. Kevans D., Murthy S., Iaccono A., et al. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology 2012, 142(Suppl 1):S384-S385.
31. Fasanmade A.A., Adedokun O.J., Blank M., et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011, 33:946-964.
32. Takeuchi T., Miyasaka N., Tatsuki Y., et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:1208-1215.
33. Olsen T., Goll R., Cui G., et al. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine 2009, 46:222-227.
34. Jamnitski A., Bartelds G.M., Nurmohamed M.T., et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011, 70:284-288.
35. Ternant D., Aubourg A., Magdelaine-Beuzelin C., et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008, 30:523-529.
36. Klaasen R., Wijbrandts C.A., Gerlag D.M., et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011, 63:359-364.
37. Bultman E., de Haar C., van Liere-Baron A., et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012, 35:335-341.
38. Peyrin-Biroulet L., Gonzalez F., Dubuquoy L., et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012, 61:78-85.
39. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 2005, 34:12-18.
40. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333. quiz, 591.
41. Reinisch W., Feagan B.G., Rutgeerts P., et al. Infliximab concentration and clinical outcome in patients with ulcerative colitis. Gastroenterology 2012, 142(Suppl 1). S-114.
42. Afif W., Loftus E.V., Faubion W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
43. Steenholdt C., Al-Khalaf M., Brynskov J., et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012 Feb 16, Epub ahead of print.
44. Vande Casteele N., Cuypers L., Singh S., et al. Antibodies to infliximab can either be persistent or transient: a retrospective case-control study in IBD patients treated with infliximab maintenance therapy. Gastroenterology 2012, 142(Suppl 1). S-114.
45. Vande Casteele N., Ballet V., Van Assche G., et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012, 61:321. author reply, 322.
46. Feagan B.G., Greenberg G., Singh S., et al. Novel infliximab and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease. Gastroenterology 2012, 142(Suppl 1). S-114.
47. Sandborn W.J., Hanauer S.B., Pierre-Louis B., et al. Certolizumab pegol plasma concentration and clinical remission in Crohn's disease. Gastroenterology 2012, 142(Suppl 1). S-563.
48. Vande Casteele N., Compernolle G., Ballet V., et al. Results on the optimisation phase of the prospective controlled Trough Level Adapted Infliximab Treatment (TAXIT) trial. Gastroenterology 2012, 142(Suppl 1):S211-S212.
49. Ordás I., Mould D.R., Feagan B.G., et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012, 91:635-646.